Revenue Breakdown
Composition ()
No data
Revenue Streams
ACADIA Pharmaceuticals Inc (ACAD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is NUPLAZID, accounting for 63.7% of total sales, equivalent to $177.53M. Another important revenue stream is DAYBUE. Understanding this composition is critical for investors evaluating how ACAD navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, ACADIA Pharmaceuticals Inc maintains a gross margin of 90.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.12%, while the net margin is 96.33%. These profitability ratios, combined with a Return on Equity (ROE) of 39.89%, provide a clear picture of how effectively ACAD converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ACAD competes directly with industry leaders such as ERAS and INDV. With a market capitalization of $4.19B, it holds a leading position in the sector. When comparing efficiency, ACAD's gross margin of 90.77% stands against ERAS's N/A and INDV's 73.57%. Such benchmarking helps identify whether ACADIA Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
